EugÃ¨ne P Van Puijenbroek

List of Publications by Year
in descending order

109 papers	3,268 citations	236612 25 h-index	168136 53 g-index
110 all docs	110 docs citations	110 times ranked	2426 citing authors

#	Article	IF	Citations
1	Neuropsychiatric adverse drug reactions associated with low dose methotrexate in rheumatoid arthritis patients. Expert Opinion on Drug Safety, 2022, 21, 417-423.	1.0	3
2	Barriers and facilitators for systematically registering adverse drug reactions in electronic health records: a qualitative study with Dutch healthcare professionals. Expert Opinion on Drug Safety, 2022, 21, 699-706.	1.0	5
3	Post-Marketing Safety Profile of Vortioxetine Using a Cluster Analysis and a Disproportionality Analysis of Global Adverse Event Reports. Drug Safety, 2022, 45, 145-153.	1.4	9
4	Electronic Health Recordâ€“Triggered Research Infrastructure Combining Real-world Electronic Health Record Data and Patient-Reported Outcomes to Detect Benefits, Risks, and Impact of Medication: Development Study. JMIR Medical Informatics, 2022, 10, e33250.	1.3	1
5	Evaluation of pharmacovigilance systems for reporting medication errors in Africa and the role of patients using a mixed-methods approach. PLoS ONE, 2022, 17, e0264699.	1.1	4
6	Hypoglycaemia following JAK inhibitor treatment in patients with diabetes. Annals of the Rheumatic Diseases, 2022, 81, 597-599.	0.5	5
7	Sex Differences in Reported Adverse Drug Reactions to Angiotensin-Converting Enzyme Inhibitors. JAMA Network Open, 2022, 5, e228224.	2.8	10
8	Retroperitoneal fibrosis and Î²â€blocking agents: Is there an association?. British Journal of Clinical Pharmacology, 2021, 87, 2891-2901.	1.1	1
9	Patient-Reported Adverse Events of Radiopharmaceuticals: A Prospective Study of 1002 Patients. Drug Safety, 2021, 44, 211-222.	1.4	4
10	Economic evaluations of chronic obstructive pulmonary disease pharmacotherapy: how well are the real-world issues of medication adherence, comorbidities and adverse drug-reactions addressed?. Expert Opinion on Pharmacotherapy, 2021, 22, 923-935.	0.9	3
11	Comparative Assessment of the Pharmacovigilance Systems within the Neglected Tropical Diseases Programs in East Africaâ€”Ethiopia, Kenya, Rwanda, and Tanzania. International Journal of Environmental Research and Public Health, 2021, 18, 1941.	1.2	9
12	Inclusion of Safety-Related Issues in Economic Evaluations for Seasonal Influenza Vaccines: A Systematic Review. Vaccines, 2021, 9, 111.	2.1	3
13	Efficacy, Safety, and Economics of Innovative Medicines: The Role of Multi-Criteria Decision Analysis and Managed Entry Agreements in Practice and Policy. Frontiers in Medical Technology, 2021, 3, 629750.	1.3	4
14	Gastrointestinal Adverse Drug Reaction Profile of Etanercept: Real-world Data From Patients and Healthcare Professionals. Journal of Rheumatology, 2021, 48, 1388-1394.	1.0	2
15	The International Pharmacy Game: A Comparison of Implementation in Seven Universities World-Wide. Pharmacy (Basel, Switzerland), 2021, 9, 125.	0.6	11
16	Numbers of spontaneous reports: how to use and interpret?. British Journal of Clinical Pharmacology, 2021, , .	1.1	10
17	Safe use of radiopharmaceuticals in patients with chronic kidney disease: a systematic review. EJNMMI Radiopharmacy and Chemistry, 2021, 6, 27.	1.8	2
18	Patientsâ€™ perspectives on a drug safety monitoring system for immune-mediated inflammatory diseases based on patient-reported outcomes. Expert Opinion on Drug Safety, 2021, 20, 1-8.	1.0	0

#	Article	IF	Citations
19	Patient-Reported Adverse Events of Radiopharmaceuticals: Development and Validation of a Questionnaire. Drug Safety, 2020, 43, 319-328.	1.4	1
20	Male Sexual Health and Reproduction in Cutaneous Immune-Mediated Diseases: A Systematic Review. Sexual Medicine Reviews, 2020, 9, 423-433.	1.5	4
21	Frequency of real-world reported adverse drug reactions in rheumatoid arthritis patients. Expert Opinion on Drug Safety, 2020, 19, 1617-1624.	1.0	9
22	Stakeholdersâ€™ perspectives on a patient-reported outcome measure-based drug safety monitoring system for immune-mediated inflammatory diseases. Expert Opinion on Drug Safety, 2020, 19, 1521-1528.	1.0	2
23	Discontinuation of metformin to prevent metformin-induced high colonic FDG uptake: is 48Âh sufficient?. Annals of Nuclear Medicine, 2020, 34, 833-839.	1.2	5
24	Patient-Reported Burden of Adverse Drug Reactions Attributed to Biologics Used for Immune-Mediated Inflammatory Diseases. Drug Safety, 2020, 43, 917-925.	1.4	20
25	Immune-mediated inflammatory disease patientsâ€™ preferences in adverse drug reaction information regarding biologics. Expert Opinion on Drug Safety, 2020, 19, 1049-1054.	1.0	6
26	Impact of a Forced Dose-Equivalent Levothyroxine Brand Switch on Plasma Thyrotropin: A Cohort Study. Thyroid, 2020, 30, 821-828.	2.4	17
27	Sex Differences in Adverse Drug Reactions of Metformin: A Longitudinal Survey Study. Drug Safety, 2020, 43, 489-495.	1.4	34
28	Comparative Assessment of the National Pharmacovigilance Systems in East Africa: Ethiopia, Kenya, Rwanda and Tanzania. Drug Safety, 2020, 43, 339-350.	1.4	30
29	Safety profile of non-vitamin K oral anticoagulants (NOACs) from a patient perspective: a web-based cohort event monitoring study. Expert Opinion on Drug Safety, 2019, 18, 869-874.	1.0	1
30	Assessment of medication use during pregnancy by Web-based questionnaires, pharmacy records and serum screening. Reproductive Toxicology, 2019, 84, 93-97.	1.3	4
31	Adverse Events of Diagnostic Radiopharmaceuticals: A Systematic Review. Seminars in Nuclear Medicine, 2019, 49, 382-410.	2.5	9
32	Patient preferences and expectation for feedback on adverse drug reaction reports submitted in Ghana. Ghana Medical Journal, 2019, 53, 150.	0.1	4
33	Adverse drug event patterns experienced by patients with diabetes: A diary study in primary care. Pharmacoepidemiology and Drug Safety, 2019, 28, 1175-1179.	0.9	8
34	Time to onset in statistical signal detection revisited: A followâ€up study in longâ€term onset adverse drug reactions. Pharmacoepidemiology and Drug Safety, 2019, 28, 1283-1289.	0.9	4
35	Anaphylactic Reaction to Tc-99m Macrosalb. Drug Safety - Case Reports, 2019, 6, 4.	0.9	1
36	Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: An explorative observational study. British Journal of Clinical Pharmacology, 2019, 85, 1507-1515.	1.1	89

#	Article	IF	Citations
37	Workshop on the Italian Pharmacovigilance System in the International Context: Critical Issues and Perspectives. Drug Safety, 2019, 42, 683-687.	1.4	2
38	A prediction modelâ€based algorithm for computerâ€assisted database screening of adverse drug reactions in the Netherlands. Pharmacoepidemiology and Drug Safety, 2018, 27, 199-205.	0.9	19
39	Sex Differences in Reported Adverse Drug Reactions of Selective Serotonin Reuptake Inhibitors. Drug Safety, 2018, 41, 677-683.	1.4	22
40	Does patient reporting lead to earlier detection of drug safety signals? A retrospective comparison of time to reporting between patients and healthcare professionals in a global database. British Journal of Clinical Pharmacology, 2018, 84, 1514-1524.	1.1	15
41	The adverse drug reaction reporting assignment for specialist oncology nurses: a preliminary evaluation of quality, relevance and educational value in a prospective cohort study. Naunyn-Schmiedeberg's Archives of Pharmacology, 2018, 391, 17-26.	1.4	16
42	When More Is Less: An Exploratory Study of the Precautionary Reporting Bias and Its Impact on Safety Signal Detection. Clinical Pharmacology and Therapeutics, 2018, 103, 296-303.	2.3	17
43	Vitamin B6 in Health Supplements and Neuropathy: Case Series Assessment of Spontaneously Reported Cases. Drug Safety, 2018, 41, 859-869.	1.4	27
44	Feasibility and Educational Value of a Student-Run Pharmacovigilance Programme: A Prospective Cohort Study. Drug Safety, 2017, 40, 409-418.	1.4	22
45	The Quality of Clinical Information in Adverse Drug Reaction Reports by Patients and Healthcare Professionals: A Retrospective Comparative Analysis. Drug Safety, 2017, 40, 607-614.	1.4	63
46	Pharmacovigilance Skills, Knowledge and Attitudes in our Future Doctors â€“ A Nationwide Study in the Netherlands. Basic and Clinical Pharmacology and Toxicology, 2017, 120, 475-481.	1.2	19
47	A global view of undergraduate education in pharmacovigilance. European Journal of Clinical Pharmacology, 2017, 73, 891-899.	0.8	26
48	Web-based questionnaires to assess perinatal outcome proved to be valid. Journal of Clinical Epidemiology, 2017, 90, 136-143.	2.4	18
49	Patientsâ€™ Perspectives on Adverse Drug Reaction Reporting in a Developing Country: A Case Study from Ghana. Drug Safety, 2017, 40, 911-921.	1.4	18
50	Broadening the Scope of Pharmacovigilance. , 2017, , 131-144.		1
51	Contraindicated use of 5â€alphaâ€reductase inhibitors in women. British Journal of Clinical Pharmacology, 2017, 83, 429-431.	1.1	3
52	The Impact of Experiencing Adverse Drug Reactions on the Patientâ€™s Quality of Life: A Retrospective Cross-Sectional Study in the Netherlands. Drug Safety, 2016, 39, 769-776.	1.4	40
53	The value of timeâ€toâ€onset in statistical signal detection of adverse drug reactions: a comparison with disproportionality analysis in spontaneous reports from the Netherlands. Pharmacoepidemiology and Drug Safety, 2016, 25, 1361-1367.	0.9	14
54	Actions in response to drug safety signalsÂarising from a spontaneous reportingÂsystem: Retrospective studyÂinÂTheÂNetherlands. International Journal of Risk and Safety in Medicine, 2016, 28, 115-123.	0.3	3

#	Article	IF	Citations
55	Response to the validity and reliability of a signal impact assessment tool: statistical issue to avoid misinterpretation. Pharmacoepidemiology and Drug Safety, 2016, 25, 1217-1217.	0.9	0
56	The validity and reliability of a signal impact assessment tool. Pharmacoepidemiology and Drug Safety, 2016, 25, 815-819.	0.9	11
57	Time course, outcome and management of adverse drug reactions associated with metformin from patientâ€™s perspective: a prospective, observational cohort study in the Netherlands. European Journal of Clinical Pharmacology, 2016, 72, 615-622.	0.8	18
58	Adverse drug reaction reports of patients and healthcare professionalsâ€"differences in reported information. Pharmacoepidemiology and Drug Safety, 2015, 24, 152-158.	0.9	54
59	Parametric time-to-onset models were developed to improve causality assessment of adverse drug reactions from antidiabetic drugs. Journal of Clinical Epidemiology, 2015, 68, 1423-1431.	2.4	3
60	Relationship Between Structural Alerts in NSAIDs and Idiosyncratic Hepatotoxicity: An Analysis of Spontaneous Report Data from the WHO Database. Drug Safety, 2015, 38, 511-515.	1.4	7
61	Feedback for patients reporting adverse drug reactions; satisfaction and expectations. Expert Opinion on Drug Safety, 2015, 14, 625-632.	1.0	9
62	Six cases of (severe) hypoglycaemia associated with gabapentin use in both diabetic and nonâ€diabetic patients. British Journal of Clinical Pharmacology, 2015, 79, 870-871.	1.1	14
63	Important information regarding reporting of adverse drug reactions: a qualitative study. International Journal of Pharmacy Practice, 2014, 22, 231-233.	0.3	23
64	Experiences with the Use of Varenicline in Daily Practice in the Netherlands: A Prospective, Observational Cohort Study. Drug Safety, 2014, 37, 449-457.	1.4	10
65	Adjuvanted A/H1N1 (2009) influenza vaccination during pregnancy: Description of a prospective cohort and spontaneously reported pregnancyâ€related adverse reactions in the Netherlands. Birth Defects Research Part A: Clinical and Molecular Teratology, 2014, 100, 731-738.	1.6	10
66	Intensive monitoring of duloxetine: results of a web-based intensive monitoring study. European Journal of Clinical Pharmacology, 2013, 69, 209-215.	0.8	24
67	Representativeness of diabetes patients participating in a webâ€based adverse drug reaction monitoring system. Pharmacoepidemiology and Drug Safety, 2013, 22, 250-255.	0.9	8
68	Hearing Impairment Associated with Oral Terbinafine Use. Drug Safety, 2012, 35, 685-691.	1.4	5
69	Spontaneous ejaculation with the use of noradrenergic reuptake inhibitors. European Journal of Clinical Pharmacology, 2012, 68, 1461-1462.	0.8	9
70	Hearing Impairment Associated with Oral Terbinafine Use. Drug Safety, 2012, 35, 685-691.	1.4	5
71	Intensive Monitoring of Pregabalin. Drug Safety, 2011, 34, 221-231.	1.4	33
72	Uterine Perforation with the Levonorgestrel-Releasing Intrauterine Device. Drug Safety, 2011, 34, 83-88.	1.4	28

#	Article	IF	Citations
73	Effectiveness of Pharmacovigilance Training of General Practitioners. Drug Safety, 2011, 34, 755-762.	1.4	25
74	Expectations for Feedback in Adverse Drug Reporting by Healthcare Professionals in the Netherlands. Drug Safety, 2011, 35, 1.	1.4	17
75	Monitoring adverse events of vaccines against Mexican flu. International Journal of Risk and Safety in Medicine, 2011, 23, 81-87.	0.3	4
76	The proportion of patient reports of suspected ADRs to signal detection in the Netherlands: caseâ€“control study. Pharmacoepidemiology and Drug Safety, 2011, 20, 286-291.	0.9	47
77	Longitudinal monitoring of the safety of drugs by using a webâ€based system: the case of pregabalin. Pharmacoepidemiology and Drug Safety, 2011, 20, 591-597.	0.9	29
78	Motives for reporting adverse drug reactions by patient-reporters in the Netherlands. European Journal of Clinical Pharmacology, 2010, 66, 1143-1150.	0.8	65
79	Media attention and the influence on the reporting odds ratio in disproportionality analysis: an example of patient reporting of statins. Pharmacoepidemiology and Drug Safety, 2010, 19, 26-32.	0.9	27
80	Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) or Hyponatraemia Associated with Valproic Acid. Drug Safety, 2010, 33, 47-55.	1.4	27
81	Hyponatraemia as an Adverse Drug Reaction of Antipsychotic Drugs. Drug Safety, 2010, 33, 569-578.	1.4	51
82	Monitoring Adverse Events of the Vaccination Campaign Against Influenza A (H1N1) in the Netherlands. Drug Safety, 2010, 33, 1097-1108.	1.4	26
83	Fever Following Immunization with Influenza A (H1N1) Vaccine in Children. Drug Safety, 2010, 33, 1109-1115.	1.4	15
84	Spontaneous ADR Reports as a Trigger for Pharmacogenetic Research. Drug Safety, 2009, 32, 255-264.	1.4	15
85	Spontaneous Reports and Pharmacogenetics. Drug Safety, 2009, 32, 357-358.	1.4	3
86	Reporting of Adverse Drug Reactions by General Practitioners. Drug Safety, 2009, 32, 851-858.	1.4	29
87	Expectations of general practitioners and specialist doctors regarding the feedback received after reporting an adverse drug reaction. Pharmacoepidemiology and Drug Safety, 2008, 17, 76-81.	0.9	8
88	Influence of Chemical Structure on Hypersensitivity Reactions Induced by Antiepileptic Drugs. Drug Safety, 2008, 31, 695-702.	1.4	42
89	Drug-Related Nephrotoxic and Ototoxic Reactions. Drug Safety, 2008, 31, 877-884.	1.4	19
90	Clindamycin and taste disorders. British Journal of Clinical Pharmacology, 2007, 64, 542-545.	1.1	16

#	Article	IF	Citations
91	Post Launch Monitoring of food products: What can be learned from pharmacovigilance. Regulatory Toxicology and Pharmacology, 2007, 47, 213-220.	1.3	8
92	Pharmacogenetics of drug-induced arrhythmias: a feasibility study using spontaneous adverse drug reactions reporting data. Pharmacoepidemiology and Drug Safety, 2006, 15, 99-105.	0.9	9
93	Data mining in pharmacovigilance: lessons from phantom ships. European Journal of Clinical Pharmacology, 2006, 62, 967-970.	0.8	19
94	Mirtazapine-induced arthralgia. British Journal of Clinical Pharmacology, 2005, 60, 570-572.	1.1	4
95	The role of data mining in pharmacovigilance. Expert Opinion on Drug Safety, 2005, 4, 929-948.	1.0	211
96	Slipped capital femoral epiphyses associated with the withdrawal of a gonadotrophin releasing hormone. BMJ: British Medical Journal, 2004, 328, 1353.	2.4	10
97	Photo-onycholysis associated with the use of doxycycline. BMJ: British Medical Journal, 2004, 329, 265.1.	2.4	33
98	Do pharmacistsâ€™ reports of adverse drug reactions reflect patientsâ€™ concerns?. International Journal of Clinical Pharmacy, 2004, 26, 155-159.	1.4	17
99	The Weber-curve pitfall: effects of a forced introduction on reporting rates and reported adverse reaction profiles. International Journal of Clinical Pharmacy, 2003, 25, 260-263.	1.4	16
100	Application of Quantitative Signal Detection in the Dutch Spontaneous Reporting System for Adverse Drug Reactions. Drug Safety, 2003, 26, 293-301.	1.4	104
101	Myopathy Due to Statin/Fibrate Use in the Netherlands. Annals of Pharmacotherapy, 2002, 36, 1957-1960.	0.9	10
102	Use of Measures of Disproportionality in Pharmacovigilance. Drug Safety, 2002, 25, 453-458.	1.4	138
103	Different Risks for NSAID-Induced Anaphylaxis. Annals of Pharmacotherapy, 2002, 36, 24-29.	0.9	50
104	On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of under-reporting on odds ratios. Statistics in Medicine, 2002, 21, 2027-2044.	0.8	115
105	A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiology and Drug Safety, 2002, 11, 3-10.	0.9	822
106	Determinants of signal selection in a spontaneous reporting system for adverse drug reactions. British Journal of Clinical Pharmacology, 2001, 52, 579-586.	1.1	54
107	Association between terbinafine and arthralgia, fever and urticaria: symptoms or syndrome?. Pharmacoepidemiology and Drug Safety, 2001, 10, 135-142.	0.9	20
108	Detecting drugâ€“drug interactions using a database for spontaneous adverse drug reactions: an example with diuretics and non-steroidal anti-inflammatory drugs. European Journal of Clinical Pharmacology, 2000, 56, 733-738.	0.8	105

#	Article	IF	Citations
109	Signalling possible drug-drug interactions in a spontaneous reporting system: delay of withdrawal bleeding during concomitant use of oral contraceptives and itraconazole. British Journal of Clinical Pharmacology, 1999, 47, 689-693.	1.1	108